Sobi rights issuance is meant to finance loan
The biotech company Sobi, which is listed on the Nasdaq stock exchange in Stockholm, will issue new shares for just over SEK 6bn (EUR 505m) with preferential rights rights for existing shareholders, writes Sobi in a stock exchange announcement following the company’s annual general meeting last week.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.